Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A basket trial of DS-8201a, a novel HER2-targeted antibody-drug conjugate, for HER2 amplified solid tumors identified by ctDNA analysis

Trial Profile

A basket trial of DS-8201a, a novel HER2-targeted antibody-drug conjugate, for HER2 amplified solid tumors identified by ctDNA analysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Biliary cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Salivary gland cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms HERALD

Most Recent Events

  • 24 Apr 2025 According to Daiichi Sankyo Media release, Based on data from four phase 2 trials including HERALD,DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01,the company has submitted a supplemental New Drug Application (sNDA) to Japans Ministry of Health, Labour and Welfare (MHLW) for ENHERTU(trastuzumab deruxtecan) for the treatment of adult patients with HER2 positive advanced or recurrent solid tumors refractory or intolerant to standard treatments.
  • 04 Jul 2023 Status changed to completed, as per JapicCTI record
  • 06 Jun 2023 Results (at data cut-off: July 17, 2022), presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top